Cargando…
Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial. Methods: A systematic review and meta-analysis comparing PD-(L)1 and VEGF(R) blockade combinati...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166877/ https://www.ncbi.nlm.nih.gov/pubmed/37180706 http://dx.doi.org/10.3389/fphar.2023.1093194 |
_version_ | 1785038538074488832 |
---|---|
author | Tang, Qiyu Wu, Dawei Huang, Huiyao Fang, Hong Wu, Ying Liu, Funan Li, Ning |
author_facet | Tang, Qiyu Wu, Dawei Huang, Huiyao Fang, Hong Wu, Ying Liu, Funan Li, Ning |
author_sort | Tang, Qiyu |
collection | PubMed |
description | Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial. Methods: A systematic review and meta-analysis comparing PD-(L)1 and VEGF(R) blockade combination therapy with PD-(L)1 inhibitors alone was performed. Phase II or III randomized clinical trials reporting irAEs or trAEs were included. The protocol was registered with PROSPERO, CRD42021287603. Results: Overall, 77 articles were included in the meta-analysis. A total of 31 studies involving 8,638 participants were pooled and an incidence for PD-(L)1 inhibitor monotherapy with any grade and grade ≥3 irAEs of 0.25 (0.20, 0.32) and 0.06 (0.05, 0.07), respectively, were reported. Two studies with 863 participants pooled for PD-(L)1 and VEGF(R) blockade showed that an incidence of any grade and grade ≥3 irAEs were 0.47 (0.30, 0.65) and 0.11 (0.08, 0.16), respectively. Regarding pairwise comparisons for irAEs, only one study was included, indicating no significant difference between the two regimens in terms of colitis, hyperthyroidism, and hypothyroidism for any grade and grade ≥3, while there was a trend of higher incidence for any grade hyperthyroidism under the combination therapy. The incidence of reactive cutaneous capillary endothelial proliferation (RCCEP) was as high as 0.80 under camrelizumab monotherapy. Conclusion: Total incidences of any grade and grade ≥3 irAEs were higher in the combination treatment group. Direct comparisons indicated no significant difference between the two regimens for any grade and grade ≥3 specific irAEs. RCCEP and thyroid disorders need to be paid attention to clinically. Moreover, trials with direct comparisons are needed and the safety profiles of the two regimens should be further explored. Exploration of the mechanism of action and regulatory management of adverse events should be enhanced. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=287603, identifier CRD42021287603 |
format | Online Article Text |
id | pubmed-10166877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101668772023-05-10 Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis Tang, Qiyu Wu, Dawei Huang, Huiyao Fang, Hong Wu, Ying Liu, Funan Li, Ning Front Pharmacol Pharmacology Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial. Methods: A systematic review and meta-analysis comparing PD-(L)1 and VEGF(R) blockade combination therapy with PD-(L)1 inhibitors alone was performed. Phase II or III randomized clinical trials reporting irAEs or trAEs were included. The protocol was registered with PROSPERO, CRD42021287603. Results: Overall, 77 articles were included in the meta-analysis. A total of 31 studies involving 8,638 participants were pooled and an incidence for PD-(L)1 inhibitor monotherapy with any grade and grade ≥3 irAEs of 0.25 (0.20, 0.32) and 0.06 (0.05, 0.07), respectively, were reported. Two studies with 863 participants pooled for PD-(L)1 and VEGF(R) blockade showed that an incidence of any grade and grade ≥3 irAEs were 0.47 (0.30, 0.65) and 0.11 (0.08, 0.16), respectively. Regarding pairwise comparisons for irAEs, only one study was included, indicating no significant difference between the two regimens in terms of colitis, hyperthyroidism, and hypothyroidism for any grade and grade ≥3, while there was a trend of higher incidence for any grade hyperthyroidism under the combination therapy. The incidence of reactive cutaneous capillary endothelial proliferation (RCCEP) was as high as 0.80 under camrelizumab monotherapy. Conclusion: Total incidences of any grade and grade ≥3 irAEs were higher in the combination treatment group. Direct comparisons indicated no significant difference between the two regimens for any grade and grade ≥3 specific irAEs. RCCEP and thyroid disorders need to be paid attention to clinically. Moreover, trials with direct comparisons are needed and the safety profiles of the two regimens should be further explored. Exploration of the mechanism of action and regulatory management of adverse events should be enhanced. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=287603, identifier CRD42021287603 Frontiers Media S.A. 2023-04-25 /pmc/articles/PMC10166877/ /pubmed/37180706 http://dx.doi.org/10.3389/fphar.2023.1093194 Text en Copyright © 2023 Tang, Wu, Huang, Fang, Wu, Liu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Tang, Qiyu Wu, Dawei Huang, Huiyao Fang, Hong Wu, Ying Liu, Funan Li, Ning Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
title | Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
title_full | Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
title_fullStr | Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
title_full_unstemmed | Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
title_short | Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
title_sort | adverse events of pd-(l)1 inhibitors plus anti-vegf(r) agents compared with pd-(l)1 inhibitors alone for cancer patients: a systematic review and meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166877/ https://www.ncbi.nlm.nih.gov/pubmed/37180706 http://dx.doi.org/10.3389/fphar.2023.1093194 |
work_keys_str_mv | AT tangqiyu adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis AT wudawei adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis AT huanghuiyao adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis AT fanghong adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis AT wuying adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis AT liufunan adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis AT lining adverseeventsofpdl1inhibitorsplusantivegfragentscomparedwithpdl1inhibitorsaloneforcancerpatientsasystematicreviewandmetaanalysis |